SG Americas Securities LLC Has $16.09 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

SG Americas Securities LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 77.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,897 shares of the medical research company’s stock after purchasing an additional 29,602 shares during the period. SG Americas Securities LLC’s holdings in IQVIA were worth $16,090,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rise Advisors LLC bought a new stake in shares of IQVIA in the first quarter valued at approximately $31,000. Versant Capital Management Inc boosted its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Riverview Trust Co bought a new stake in shares of IQVIA in the first quarter valued at approximately $32,000. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the second quarter valued at approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA in the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.1 %

Shares of NYSE IQV traded up $2.44 during mid-day trading on Friday, hitting $229.84. The company’s stock had a trading volume of 591,239 shares, compared to its average volume of 1,077,197. The stock has a market cap of $41.88 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 2.21 and a beta of 1.49. The company’s fifty day simple moving average is $240.74 and its 200-day simple moving average is $232.70. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the company posted $2.22 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IQV shares. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Robert W. Baird raised their target price on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Evercore ISI increased their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.